Parexel, tapping new partner Datavant, pens TriNetX real-world data pact

 Why wearables, health records and clinical trials need a blockchain injection
(peshkov/iStockPhoto)

In a mix-up of trial-based solutions, CRO Parexel is using its recent partnership with Datavant to run a pact with life science data firm TriNetX.

The deal breaks down like this: Parexel signed the deal, but the heavy lifting will be done by San Francisco-based Datavant—Vivek Ramaswamy’s service firm with tech that allows the linking of traditional healthcare data sources like electronic medical records, claims and diagnostics with other emerging sources such as genomics, socioeconomic data, information from wearable devices and behavioral data.

The pair signed up to a trial workflow deal last October, and Datavant will now work with TriNetX (which incidentally also partners with Datavant) specifically to gain new insights from real-world data.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

As the three explain in a release: “Working with Parexel’s strategic partner Datavant … the integrated offering will leverage Datavant’s privacy-protecting linking technology to connect Parexel’s study operations data with de-identified data from TriNetX’s network of global healthcare organizations, streamlining access to real-world data to enhance clinical trials and deliver new therapies faster.”

Financials of the deal were not disclosed.

The idea is to make understanding these data on the ground easier and to provide access to more relevant information about what is going on, especially in the quickfire trial situation the industry has found itself in during the pandemic.

“Integrating real-world data into the clinical development process has the potential to increase the amount of information gained from each trial, and thus dramatically accelerate the drug development process,” explained Travis May, CEO of Datavant.

“We are proud to be working with both Parexel and TriNetX to enhance such real-world data studies by allowing clinical trial data to be linked to real-world data while ensuring regulatory compliance and protecting patient privacy.”

TriNetX has working deals with Sanofi and Pfizer as well as Datavant.

Suggested Articles

According to a large clinical study, multifocal contact lenses were able to slow down and control the worsening of nearsightedness in children.

RapidAI has secured an FDA clearance for its artificial intelligence algorithms that quickly parse brain CT scans and spot suspected strokes.

The kits can connect 20 standard hospital beds to a central patient monitoring station and be up and running in an average of five hours.